First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Holger Thurm et al.|New England Journal of Medicine|2020Cited by 1.1k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin Solomon, Tony Mok, Todd M. Bauer et al.|Journal of Clinical Oncology|2022Cited by 133
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i>-altered cancers.Alexander Drilon, Lori J. Wirth, Vivek Subbiah et al.|Journal of Clinical Oncology|2018Cited by 104
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81